


CV of Participant

	<p style="text-align: center;">Amalio <u>Telenti</u></p>
<p>Present Position:</p>	<p>Director, Institute of Microbiology Professor, Medical Virology</p>
<p>Organization:</p>	<p>University Hospital and University of Lausanne</p>
<p>Major Field:</p>	<p>Virology and host genetics</p>
<p>Professional history & List of 5 most important papers</p>	<p>A. Telenti, MD (Infectious Diseases) and PhD (Microbiology) trained in internal medicine and infectious diseases at the Mayo Clinic, Rochester, Minnesota; and in microbiology research at the university of Berne, Switzerland, and at the Albert Einstein College of Medicine, New York. Dr. Telenti primary scientific interest is in the field of host genetics and pharmacogenetics in HIV disease. He is editor of www.HIV-pharmacogenomics.org, member of the Swiss HIV Cohort Study, and member of the scientific executive board of SystemsX.ch, the Swiss national program for Systems Biology.</p> <p>Selected recent publications</p> <ol style="list-style-type: none"> 1. Loeuillet et al. In vitro whole genome analysis identifies a susceptibility locus for HIV-1. <i>PLoS Biol</i> 6:e32, 2008. 2. Loeuillet et al. Promoter polymorphisms and allelic imbalance in ABCB1 expression. <i>Pharmacogenetics Genomics</i> 17: 951-050, 2007. 3. Arnedo et al. Contribution of 20 SNPs of 13 genes to dyslipidemia associated with antiretroviral therapy. <i>Pharmacogenetics Genomics</i> 2007 Sep;17(9):755-764. 4. Fellay et al. Identification of major determinants of the host control of HIV-1 through a whole genome association study. <i>Science</i>, 2007 Aug 17;317(5840):944-7. 5. Rotger et al. The Predictive value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-Infected Individuals. <i>Clin Pharmacol Ther</i>, 2007, Apr;81(4):557-66.